Our study aims to assess the efficacy of Acceptance and Commitment Therapy on psychotic severity among Inpatients with primary psychosis: A Randomized Controlled Trial.

Current study was an open label, two-arm, parallel, randomized controlled trial, evaluating the efficiency of Acceptance and Commitment Therapy (ACT) added to treatment as usual (TAU) as opposed to treatment as usual (TAU) alone on patients with schizophrenia. The study adheres to the rules for writing Clinical Trials: "The Consolidated Standards of Reporting Trials" (CONSORT) statement

Inclusion criteria Participants' criteria of inclusion involved those patients who were

1. Current psychiatric hospitalization;
2. DSM-5 diagnosis of a primary psychotic disorder; (schizophrenia, schizoaffective disorder, delusional disorder, schizophreniform disorder, brief psychotic disorder, and unspecified psychotic disorder, this diagnosis was confirmed by a psychiatrist
3. 18 years or older;
4. ability to talk, read and write in Arabic; and
5. willingness to participate in the study that was scheduled for seven weeks.

Exclusion criteria Patients were excluded if they

1. had a comorbid learning disability or organic brain disorder;
2. psychosis related to a general medical condition or substance-induced psychotic disorder;
3. were considered mentally unstable; or
4. unfit to participate in the study by their therapist, and/or had newly had (been receiving) psycho-education or somewhat designed psychosocial intervention.

To ensure privacy and confidentiality of participants their data will be secured

Information is not withheld from trial participants